RBC Capital analyst Brian Abrahams lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $55 from $58 and keeps an Outperform rating on the shares. The slight timeline slippage for the company’s first phase 3 azetukalner epilepsy data to early-2026 from the second half of 2025 is slightly disappointing, but the firm still sees a favorable setup going in given solid phase 2 data, good historical translatability, and key opinion leader / survey work as well as the recent branded drug launch precedents that suggest a meaningful $1.2B revenue opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target lowered to $47 from $50 at Wells Fargo
- Confident Buy Rating for Xenon Amid X-TOLE2 Study Delays and Promising Azetukalner Results
- Xenon Pharmaceuticals Advances Clinical Programs Amid Financial Loss
- Xenon Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Trials and Financial Stability
- Closing Bell Movers: Coinbase jumps after inclusion into S&P500